| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 15 | 2025 | 136 | 6.720 |
Why?
|
| Epstein-Barr Virus Infections | 11 | 2024 | 293 | 3.450 |
Why?
|
| Burkitt Lymphoma | 9 | 2024 | 141 | 2.230 |
Why?
|
| HIV Infections | 16 | 2023 | 2076 | 2.210 |
Why?
|
| Herpesvirus 4, Human | 9 | 2024 | 674 | 2.150 |
Why?
|
| Herpesvirus 8, Human | 3 | 2023 | 52 | 1.610 |
Why?
|
| Malawi | 18 | 2025 | 426 | 1.550 |
Why?
|
| Lymphoma | 4 | 2023 | 331 | 1.510 |
Why?
|
| Histiocytosis, Langerhans-Cell | 5 | 2025 | 240 | 1.370 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2025 | 1353 | 1.210 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2024 | 226 | 1.210 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2023 | 168 | 1.190 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2021 | 149 | 1.190 |
Why?
|
| Child | 43 | 2025 | 25868 | 0.960 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2025 | 15 | 0.930 |
Why?
|
| Organ Transplantation | 2 | 2024 | 183 | 0.880 |
Why?
|
| Kasabach-Merritt Syndrome | 1 | 2023 | 16 | 0.790 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2024 | 151 | 0.780 |
Why?
|
| Lymphoma, T-Cell | 4 | 2021 | 63 | 0.720 |
Why?
|
| Adolescent | 29 | 2025 | 20573 | 0.720 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2025 | 1313 | 0.670 |
Why?
|
| Interleukin-6 | 2 | 2019 | 439 | 0.650 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 294 | 0.630 |
Why?
|
| Anemia | 2 | 2023 | 350 | 0.620 |
Why?
|
| Viral Load | 4 | 2018 | 411 | 0.590 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2020 | 272 | 0.570 |
Why?
|
| Cytokines | 3 | 2021 | 1378 | 0.540 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 146 | 0.540 |
Why?
|
| Humans | 55 | 2025 | 133373 | 0.520 |
Why?
|
| Vincristine | 5 | 2020 | 196 | 0.500 |
Why?
|
| Child, Preschool | 18 | 2025 | 14873 | 0.460 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1849 | 0.420 |
Why?
|
| Lymphoma, B-Cell | 2 | 2025 | 149 | 0.400 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 5 | 2025 | 1191 | 0.380 |
Why?
|
| Rituximab | 3 | 2024 | 165 | 0.380 |
Why?
|
| Methotrexate | 3 | 2025 | 355 | 0.370 |
Why?
|
| Neoplasms | 4 | 2025 | 2992 | 0.360 |
Why?
|
| Male | 29 | 2025 | 65592 | 0.360 |
Why?
|
| Hydroa Vacciniforme | 1 | 2010 | 3 | 0.340 |
Why?
|
| Female | 29 | 2025 | 71503 | 0.330 |
Why?
|
| Infant | 11 | 2025 | 13243 | 0.320 |
Why?
|
| Young Adult | 13 | 2025 | 9923 | 0.320 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 2020 | 130 | 0.310 |
Why?
|
| Disease Management | 2 | 2025 | 565 | 0.310 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2025 | 222 | 0.300 |
Why?
|
| Retrospective Studies | 10 | 2025 | 17568 | 0.300 |
Why?
|
| Tanzania | 3 | 2023 | 73 | 0.280 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2010 | 520 | 0.270 |
Why?
|
| Bone Marrow | 3 | 2021 | 333 | 0.260 |
Why?
|
| Prognosis | 6 | 2025 | 5044 | 0.260 |
Why?
|
| Recurrence | 3 | 2025 | 1469 | 0.260 |
Why?
|
| Neoplasm Staging | 3 | 2019 | 1364 | 0.250 |
Why?
|
| Prospective Studies | 8 | 2025 | 6582 | 0.250 |
Why?
|
| Immunotherapy | 4 | 2022 | 750 | 0.240 |
Why?
|
| Survival Rate | 5 | 2025 | 2207 | 0.240 |
Why?
|
| Laboratories, Hospital | 1 | 2025 | 24 | 0.230 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 896 | 0.230 |
Why?
|
| Doxorubicin | 3 | 2020 | 301 | 0.210 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2025 | 356 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 910 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 181 | 0.210 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2025 | 197 | 0.210 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2023 | 3 | 0.200 |
Why?
|
| Cyclophosphamide | 3 | 2020 | 426 | 0.200 |
Why?
|
| Adult | 10 | 2025 | 31684 | 0.200 |
Why?
|
| Mycosis Fungoides | 1 | 2023 | 15 | 0.200 |
Why?
|
| Treatment Outcome | 11 | 2025 | 13103 | 0.200 |
Why?
|
| Mucositis | 1 | 2022 | 19 | 0.200 |
Why?
|
| HIV-1 | 2 | 2016 | 489 | 0.200 |
Why?
|
| Morbidity | 1 | 2023 | 255 | 0.190 |
Why?
|
| Haploinsufficiency | 1 | 2024 | 274 | 0.190 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 129 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 323 | 0.190 |
Why?
|
| Neurodegenerative Diseases | 1 | 2025 | 284 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2025 | 5443 | 0.190 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 363 | 0.190 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 407 | 0.190 |
Why?
|
| Perforin | 1 | 2021 | 26 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2023 | 245 | 0.180 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 357 | 0.170 |
Why?
|
| Cysticercosis | 1 | 2020 | 22 | 0.160 |
Why?
|
| Virus Replication | 1 | 2023 | 634 | 0.160 |
Why?
|
| Bleomycin | 2 | 2020 | 114 | 0.160 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 211 | 0.160 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 66 | 0.160 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 31 | 0.160 |
Why?
|
| Anthracyclines | 2 | 2017 | 44 | 0.160 |
Why?
|
| Tertiary Healthcare | 1 | 2019 | 20 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 612 | 0.150 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 300 | 0.150 |
Why?
|
| Endemic Diseases | 1 | 2018 | 59 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 47 | 0.150 |
Why?
|
| Virus Activation | 1 | 2018 | 85 | 0.140 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 350 | 0.140 |
Why?
|
| Biopsy | 1 | 2021 | 1204 | 0.140 |
Why?
|
| Withholding Treatment | 1 | 2017 | 69 | 0.130 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 295 | 0.130 |
Why?
|
| Asia | 1 | 2017 | 125 | 0.130 |
Why?
|
| Plasma | 1 | 2017 | 105 | 0.130 |
Why?
|
| Europe | 1 | 2017 | 374 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 193 | 0.120 |
Why?
|
| Risk | 1 | 2017 | 782 | 0.120 |
Why?
|
| Developing Countries | 1 | 2017 | 291 | 0.120 |
Why?
|
| Remission Induction | 1 | 2016 | 307 | 0.120 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2014 | 3 | 0.110 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3740 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2018 | 1469 | 0.110 |
Why?
|
| Algorithms | 1 | 2021 | 1730 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 10954 | 0.110 |
Why?
|
| T-Lymphocytes | 3 | 2019 | 1770 | 0.110 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 367 | 0.100 |
Why?
|
| Child Health Services | 1 | 2013 | 88 | 0.100 |
Why?
|
| Biomarkers | 1 | 2021 | 3415 | 0.090 |
Why?
|
| Adenoviridae Infections | 1 | 2011 | 71 | 0.090 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 237 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 605 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 3363 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2025 | 8632 | 0.080 |
Why?
|
| DNA, Viral | 3 | 2017 | 496 | 0.080 |
Why?
|
| United States | 2 | 2023 | 11722 | 0.080 |
Why?
|
| Genomics | 1 | 2017 | 1676 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1156 | 0.070 |
Why?
|
| Transcriptome | 1 | 2014 | 1135 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1973 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 818 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2018 | 237 | 0.070 |
Why?
|
| Mutation | 1 | 2021 | 6343 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2014 | 2559 | 0.070 |
Why?
|
| Cell Differentiation | 1 | 2014 | 2026 | 0.070 |
Why?
|
| Prednisone | 2 | 2019 | 256 | 0.070 |
Why?
|
| Cell Line, Tumor | 1 | 2014 | 3794 | 0.070 |
Why?
|
| Time Factors | 1 | 2016 | 6544 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2017 | 4917 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2016 | 965 | 0.050 |
Why?
|
| Lymph Nodes | 2 | 2019 | 395 | 0.050 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 39 | 0.050 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 33 | 0.050 |
Why?
|
| Treatment Failure | 1 | 2025 | 362 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 82 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2025 | 185 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 102 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2024 | 196 | 0.050 |
Why?
|
| Middle Aged | 5 | 2025 | 28985 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2024 | 245 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 202 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2024 | 1693 | 0.050 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 288 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 144 | 0.040 |
Why?
|
| Transplantation Conditioning | 1 | 2022 | 300 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2022 | 251 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 418 | 0.040 |
Why?
|
| Anticestodal Agents | 1 | 2020 | 3 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 184 | 0.040 |
Why?
|
| Praziquantel | 1 | 2020 | 12 | 0.040 |
Why?
|
| Subcutaneous Tissue | 1 | 2020 | 16 | 0.040 |
Why?
|
| Taenia solium | 1 | 2020 | 11 | 0.040 |
Why?
|
| Chromatin | 1 | 2024 | 617 | 0.040 |
Why?
|
| Albendazole | 1 | 2020 | 29 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 181 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 143 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 236 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 305 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 860 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2017 | 36 | 0.030 |
Why?
|
| Anti-Retroviral Agents | 1 | 2019 | 154 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 1341 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1165 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 126 | 0.030 |
Why?
|
| Viremia | 1 | 2016 | 134 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 491 | 0.030 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2014 | 3 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2014 | 40 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 62 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 1101 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 3718 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2024 | 2720 | 0.030 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 182 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2014 | 240 | 0.030 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 216 | 0.030 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.030 |
Why?
|
| Botswana | 1 | 2013 | 76 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1473 | 0.030 |
Why?
|
| Child Nutrition Disorders | 1 | 2013 | 77 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 1608 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1513 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 1353 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 659 | 0.020 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 99 | 0.020 |
Why?
|
| Liver | 1 | 2019 | 1860 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2014 | 805 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 237 | 0.020 |
Why?
|
| Japan | 1 | 2011 | 152 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 504 | 0.020 |
Why?
|
| Incidence | 1 | 2018 | 3395 | 0.020 |
Why?
|
| Animals | 2 | 2024 | 36222 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 1915 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 651 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 231 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 2956 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2011 | 562 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 1137 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 781 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2014 | 1049 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2011 | 542 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 815 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2011 | 1583 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1310 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7602 | 0.020 |
Why?
|
| Mice | 1 | 2024 | 18936 | 0.020 |
Why?
|
| Graft vs Host Disease | 1 | 2011 | 619 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 1236 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2010 | 1731 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 21500 | 0.010 |
Why?
|